Abbott India Profit Soars by 56%!

Bangalore-based pharmaceutical giant Abbott India on Thursday released its second quarter financial results, showing significant profit growth. This increase was mainly driven by strong demand for its gastrointestinal and anti-infective drugs. The company's division that makes Digene, the famous antacid drug, reported a profit of 3.59 billion rupees in the quarter ended Sept. 30, up nearly 56 percent from 2.30 billion rupees a year earlier. At the same time, the operating income for the quarter also achieved a significant increase of Rs 939.6 crore to Rs 16.33 crore from Rs 15.39 crore in the same period last year.

Abbott India, as a drugmaker like Abbott India, relies on the Indian market for most of its revenue streams. Meanwhile, rival GlaxoSmithKline Pharma is also largely dependent on revenue from the Indian market. In its latest financial report, Abbott India said it has raised the prices of certain drugs in the "Essential medicines list" that are not included in the Indian government's pricing restrictions in a bid to boost its earnings.

The company further noted in the report that the Indian market continues to benefit from growing demand for anti-infective and gastrointestinal drugs, especially for generics and vaccines. This increase in demand not only resulted in significant profit growth for Abbott India, but also reflected the important position of the Indian market in the pharmaceutical industry. As market demand continues to grow, Abbott India is expected to continue its strong performance in the future.